Friday October 1st 2021



S-Biomedic, a clinical-stage skin microbiome company, announces the completion of its bridge financing led by the European Innovation Council Fund.

The European Innovation Council (EIC) Fund and S-Biomedic N.V. have signed a convertible loan agreement to enable the completion of two development programs and kick start the commercialization of the skincare products of the company. This bridge financing round is further extended through existing shareholders and a new investor who confirm their commitment, propelling S-Biomedic to move into its next phase of growth.

Veronika Oudova, the co-founder and Chief Executive Officer of S-Biomedic, commented, “We are pleased to have completed this prestigious EIC Fund financing which allows us to progress our joint developments with our existing partners DSM and Beiersdorf. It will further enable us to focus on our commercial activities. With these funds, we will bring our first LiveSkin™ Probiotics for acne to our customers before the end of the year and right after we are ready to launch our unique patented anti-ageing active ingredient, which will be the second product coming out of our technology platform. It is a great start for the fundraising activities of our upcoming Series B round.”

Chief Commercial Officer of S-Biomedic Wesley Carpentier commented, “We are extremely pleased to receive such support and endorsement from EIC Fund. This financing demonstrates the willingness of the European Union to support pioneering life-science businesses, even in novel fields such as skin microbiome cosmetics and dermatology.”

Kinga Stanislawska, member of the EIC Fund Investment Committee, added “ We are glad to be part of S-Biomedic journey towards the commercialization of its skincare products. The EIC Fund support witnesses the EU commitment in helping the EU innovators to scaleup and unlock the talent across all of Europe’s regions and from women innovators.”

About S-Biomedic

S-Biomedic is a life-science company at the forefront of skin microbiome research and commercialization. The company harnesses the natural beneficial skin-microbiome interactions to maintain skin health and address skin disease. In 2016 the team successfully conducted the 1st skin microbiome transplantation analogous to the famous gut microbiome transplantation (Paetzold et al., 2019 in Microbiome). Today the company develops Live Skin™ probiotics and postbiotic fermentation products addressing unmet needs in dermatology as well as the cosmetic skincare industry. More information on

About the Skin Microbiome

S-Biomedic is pioneering skin-microbiome intrinsic skincare through effective dermatologically active ingredients ‘informed’ by and based on the natural skin microbiome.

While the skin is the human body’s largest organ, the microbiome is has been described as the newly discovered organ of the human body. Just like in our gut, the bacteria on our skin have many intimate and intricate interactions that are key to our skin health. These bacteria are called skin commensal means microorganisms that are commonly found on the skin. A balanced ecosystem of these skin commensals helps protect our skin from infection. When it is imbalanced, we speak of microbiome dysbiosis, which is associated with skin ageing and skin disease. Multiple studies are increasingly finding correlations between the composition of the skin microbiome and skin ageing, skin problems and a wide range of skin diseases, including acne, atopic dermatitis, eczema, rosacea and more.

About EIC Fund

Established in June 2020, the European Innovation Council Fund (EIC Fund) is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500.000 and €15 million) in European high impact and deep tech start-ups and scale ups. With a long-term perspective, the EIC Fund invests in companies from any sector, across all EU member states as well as in associated countries.

The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialization of disruptive technologies. This is achieved by crowding-in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.

The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.